Skip to content

Evaluation of the clinical efficacy of Shenshuaining capsule in the treatment of end-stage renal disease with peritoneal dialysis

Evaluation of the clinical efficacy of Shenshuaining capsule in the treatment of end-stage renal disease with peritoneal dialysis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027827
Enrollment
Unknown
Registered
2019-11-30
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage renal disease

Interventions

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years male and female; 2. Clear consciousness; 3. Regular peritoneal dialysis was performed and the urine volume was > 100ml at 24 hours; 4. Patients with stable condition who insist on regular review of relevant indicators every 3 months; 5. Volunteer to participate in this study and sign the informed consent; 6. Chinese medicine dialectic is the spleen of the spleen or the spleen and blood bruising.

Exclusion criteria

Exclusion criteria: 1. Allergic constitution or allergic to a variety of drugs; 2. There are serious digestive tract diseases that affect drug absorption,such as active ulcer,Chronic diarrhea,etc.; 3. A woman who is pregnant or breast-feeding; 4. Inability to cooperate, as with a psychopath; 5. Alcohol or drug abusers; 6. Patients who had been given Niaoduqing Particles before enrollment; 7. Drugs containing rhubarb were used before enrollment or during the trial.

Design outcomes

Primary

MeasureTime frame
Serum phosphorus;Parathyroid hormone;

Secondary

MeasureTime frame
hemoglobin;creatinine;blood urea nitrogen;ß2 microglobulin;ferritin;Serum calcium;Transferrin saturation;C-reactive protein;

Countries

China

Contacts

Public ContactShaoqing Wang

The First Affiliated Hospital of Chengdu Medical College

158468931@qq.com+86 18010594916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026